氟维司群治疗绝经后转移性乳腺癌患者的效果分析  

Efficacy Analysis of Fulvestrant in the Treatment of Postmenopausal Metastatic Breast Cancer Patients

作　　者：孙龑 马雪根[1] 钱珏[1] SUN Yan;MA Xuegen;QIAN Jue(Pharmacy Department,Suzhou Municipal Hospital,Suzhou 215001,China;不详)

机构地区：[1]苏州市立医院(南京医科大学附属苏州医院)药学部,江苏苏州215001

出　　处：《中国医学创新》2024年第33期141-145,共5页Medical Innovation of China

摘　　要：目的:探讨氟维司群治疗绝经后转移性乳腺癌(metastatic breast cancer,MBC)的效果。方法:回顾性分析2021年3月—2023年6月于苏州市立医院收治的92例绝经后MBC患者,按照治疗方案分为对照组和观察组,各46例。对照组应用醋酸亮丙瑞林微球治疗,观察组予以醋酸亮丙瑞林微球+氟维司群治疗。治疗1年后评价两组抗肿瘤疗效、血清激素水平、生存时间与无进展生存时间、毒副反应发生率、生命质量。结果:观察组客观缓解率高于对照组(P<0.05)。治疗后,两组脂质运载蛋白2(lipocalin-2,LCN-2)、六同源框1(sine oculis homeobox homolog 1,Six1)均低于治疗前,世界卫生组织生存质量测定量表简表(World Health Organization quality of life scale,WHOQOL-BREF)评分均高于治疗前,且观察组LCN-2、Six1均低于对照组,WHOQOL-BREF评分高于对照组(P<0.05)。观察组生存时间、无进展生存时间均长于对照组(P<0.05)。两组毒副反应发生率比较,差异无统计学意义(P>0.05)。结论:在绝经后MBC患者治疗中应用氟维司群,能增强抗肿瘤疗效且耐受度良好,能调节激素水平,实现延长患者生存周期、提高生命质量的治疗目的。Objective:To investigate the effect of Fluvestrant in the treatment of postmenopausal metastatic breast cancer(MBC).Method:A retrospective analysis was performed on 92 postmenopausal MBC patients admitted to Suzhou Municipal Hospital from March 2021 to June 2023,they were divided into control group and observation group according to treatment plan,with 46 cases in each group.The control group was treated with Leuprelin Acetate Microspheres,and the observation group was treated with Leuprelin Acetate Microspheres+Fluvestrant.After 1 year of treatment,the antitumor efficacy,serum hormone level,survival time,progression-free survival time,incidence of toxic and side effects and quality of life of the two groups were evaluated.Result:The objective remission rate of observation group was higher than that of control group(P<0.05).After treatment,the levels of lipocalin-2(LCN-2)and sine oculis homeobox homolog 1(Six1)in both groups were lower than those before treatment,the scores of World Health Organization quality of life scale(WHOQOL-BREF)were higher than those before treatment,LCN-2 and Six1 in observation group were lower than those in control group,and WHOQOL-BREF score was higher than that in control group(P<0.05).The survival time and progression-free survival time of observation group were longer than those of control group(P<0.05).There was no significant difference in the incidence of toxic and side effects between the two groups(P>0.05).Conclusion:The application of Fluvestrant in the treatment of postmenopausal MBC patients can enhance the anti-tumor efficacy and good tolerance,regulate hormone levels,and achieve the therapeutic purpose of prolonging the survival cycle of patients and improving the quality of life.

关 键 词：氟维司群 绝经后 转移性乳腺癌 生命质量 

分 类 号：R737.9[医药卫生—肿瘤]